The side effects of Niraparib are that it can cause a variety of discomforts in several systems of the body such as the digestive system, circulatory system, etc. This drug can be used in the treatment of epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer and other diseases. Niraparib can lead to digestive system abnormalities such as nausea, vomiting, abdominal pain, abdominal distension, dyspepsia, diarrhea, constipation, elevated alanine aminotransferase (ALT), dry mouth, fatigue, loss of appetite, etc. It can also lead to circulatory system abnormalities such as cardiac panic, hypertension, etc. Patients can also suffer from hematopoietic system abnormalities such as anemia, thrombocytopenia, and neutropenia. In addition, patients may also experience other discomforts such as insomnia, headache, arthralgia, myalgia, urinary tract infection, etc. It is contraindicated for those who are allergic to any of the components of this product. Niraparib is a polyadenosine diphosphate ribose polymerase (PARP) inhibitor, which can be used for the treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to achieve a complete remission or partial remission of first-line platinum-containing chemotherapy for the maintenance therapy. If niraparib is required, follow your doctor’s instructions for treatment.